VERAXA Biotech (NASDAQ: VRXA) announced it has received Scientific Advice from Germany’s Paul-Ehrlich-Institute regarding the underlying biology and proposed non-clinical development plan for its lead proprietary BiTAC-TCE cancer therapy program. The regulatory feedback provides greater clarity on the proposed development strategy and indicates that the agency understands the biological rationale behind the dual-targeting, conditionally active BiTAC-TCE platform, representing an early step in advancing the program toward clinical development.
The BiTAC-TCE platform is designed to selectively target cancer cells expressing both intended targets while sparing cells expressing only one target. This dual-targeting approach aims to improve the therapeutic index compared to traditional T-cell engagers, which can sometimes attack healthy cells. VERAXA highlighted preclinical data presented at the American Association for Cancer Research Annual Meeting 2026 showing that the lead BiTAC-TCE candidate demonstrated a favorable safety profile with efficacy comparable to a traditional T-cell engager, supporting the potential for an improved therapeutic index.
The Paul-Ehrlich-Institute is Germany's federal authority responsible for vaccines and biomedicines, and its scientific advice is considered a key milestone in the regulatory process. The feedback validates the company's approach and provides a clearer path forward for non-clinical development. This news is important for cancer patients and the oncology industry, as it suggests progress toward a therapy that could reduce off-target effects while maintaining potency.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL).
For investors and industry observers, this regulatory feedback could signal reduced risk in the development of VERAXA’s lead program. The company's ability to secure agency understanding early on may streamline future clinical trial design. The full press release is available at https://ibn.fm/jpXam. For the latest news and updates relating to VRXA, visit the company’s newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's filings with the SEC. The company undertakes no duty to update this information unless required by law.
